Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pyrazolopyrimidines.

C F George1

  • 1University of Western Ontario, London Health Sciences Centre, Victoria Campus, 375 South Street, London, Ontario, Canada N6A 4G5. cgeorge@uwo.ca

Lancet (London, England)
|November 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The assessment of potential drug interactions with a new tricyclic antidepressant drug.

British journal of clinical pharmacology·2012
Same author

Metabolism of terbutaline in man and dog.

British journal of clinical pharmacology·2012
Same author

Physical activity: the evidence of benefit in the prevention of coronary heart disease.

QJM : monthly journal of the Association of Physicians·2003
Same author

The implementation of Tomorrow's Doctors.

Medical education·2002
Same author

Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP.

Thorax·2001
Same author

Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.

Journal of medicinal chemistry·2001
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Newer hypnotic sedatives targeting the gamma-aminobutyric acid (GABA) receptor offer improved insomnia treatment. Pyrazolopyrimidines represent the latest advancements, providing better efficacy and fewer side effects than older medications.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Sleep Medicine

Background:

  • Pharmacological therapy is crucial for managing insomnia.
  • Older insomnia medications can cause tolerance, withdrawal, and daytime impairment.
  • Advances in understanding gamma-aminobutyric acid (GABA) receptors have driven new drug development.

Purpose of the Study:

  • To review the development and efficacy of newer hypnotic sedatives.
  • To compare the profiles of novel GABA receptor-selective agents with older insomnia drugs.
  • To highlight the potential advantages of pyrazolopyrimidines.

Main Methods:

  • Literature review of pharmacological therapies for insomnia.
  • Analysis of receptor subunit selectivity for new hypnotic agents.

Related Experiment Videos

  • Comparative assessment of efficacy and side-effect profiles.

    • Main Results:

    • Newer agents show improved hypnotic and side-effect profiles.
    • Increased selectivity for GABA receptor subunits leads to better treatment options.
    • Pyrazolopyrimidines demonstrate promising advantages over existing hypnotics.

    Conclusions:

    • Novel GABA receptor modulators offer superior insomnia management.
    • Pyrazolopyrimidines represent a significant advancement in hypnotic pharmacotherapy.
    • These newer agents provide enhanced treatment options for clinicians and patients.